{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 626"}, "official-title": {"#tail": "\n\t", "#text": "To de-link research and development incentives from drug\n\t\t  prices for new medicines to treat HIV/AIDS and to stimulate greater sharing of\n\t\t  scientific knowledge."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130320", "#text": "March 20, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "sponsor": {"#tail": " introduced\n\t\t\t the following bill; which was read twice and referred to the\n\t\t\t ", "#text": "Mr. Sanders", "@name-id": "S313"}, "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor,\n\t\t\t and Pensions"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Prize Fund for HIV/AIDS\n\t\t\t Act"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as\n\t\t\t the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short\n\t\t\t title"}, "#text": "\n      ", "@id": "S1"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " makes the following\n\t\t\t findings:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " estimates that more than 1,100,000 people are\n\t\t\t living with HIV in the United States, and that 1 in 5 of those people living\n\t\t\t with HIV is unaware of their infection.", "@entity-type": "federal-body", "#text": "Centers for\n\t\t\t Disease Control and Prevention", "@entity-id": "7523"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "id7670075aca114abb8af50315c6930659", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "An estimated\n\t\t\t 49,000 Americans become infected with HIV each year."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "idcdff18823ea743b5a6b60f6b9ea54532", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "More than 15,000\n\t\t\t people with AIDS still die each year in the United States."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "ide52af1057a8a4226bae09a0152068045", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Through 2010,\n\t\t\t more than 636,000 people with AIDS in the United States have died since the\n\t\t\t epidemic began."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "idafbab86b014f4528a41f8b3d30b66aa0", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Globally, UNAIDS\n\t\t\t estimates that more than 34,000,000 persons are living with HIV."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "id78c4af8a90474c0f840af077edcb1416", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Persons with\n\t\t\t HIV/AIDS require access to antiretroviral drugs."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "id278c8c49f161495fa0c3fd54d95707aa", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "In the United\n\t\t\t States, public and private sector expenditures on antiretroviral drugs\n\t\t\t currently exceed $9,000,000,000 per year."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "id7fd97e31e15a4c1a991387416d66ae3b", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The United States\n\t\t\t Federal Government is the largest funder of treatments for HIV/AIDS in the\n\t\t\t developing world."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "idb4be042ad42d4e4186275e21aec8521a", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The development\n\t\t\t of new medicines and vaccines for HIV/AIDS is a national priority."}, "enum": {"#tail": "\n        ", "#text": "(9)"}, "@id": "id8f15a81dd8054988b8d12f84584977b8", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Market\n\t\t\t exclusivity for new products is an expensive, inefficient, and unfair mechanism\n\t\t\t to reward investments in new products, and has created hardships for persons\n\t\t\t with HIV/AIDS and businesses that employ persons with HIV/AIDS."}, "enum": {"#tail": "\n        ", "#text": "(10)"}, "@id": "id7e650e43d19542f7b0f6e8133ed4798f", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "By de-linking\n\t\t\t research and development incentives from product prices, and by eliminating\n\t\t\t legal monopolies to sell new medicines for the treatment of HIV/AIDS, it is\n\t\t\t possible to induce investments that are medically more important, procure\n\t\t\t products at low prices from competitive suppliers, and introduce more efficient\n\t\t\t incentives for research and development."}, "enum": {"#tail": "\n        ", "#text": "(11)"}, "@id": "id3a3871ac0c6140cfa2ebb5689a7a92e4", "#text": "\n        "}], "#text": "\n      ", "@id": "IDdcee9dbe69bc419aaafd267beeebd7bd"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "It is the purpose of this Act to provide\n\t\t\t sustainable financing of incentives to encourage investments in research and\n\t\t\t development of new medicines for HIV/AIDS and to share knowledge, data,\n\t\t\t materials, and technology, through the establishment of a Prize Fund for\n\t\t\t HIV/AIDS, while enhancing access to such medicines by eliminating legal\n\t\t\t monopolies on the manufacture, distribution, and sale of such medicines.", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Purpose"}, "#text": "\n      ", "@id": "IDde914b650b554cddbf111fecf53b7ca3"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "In this Act:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " has the meaning\n\t\t\t given such term in ", "#text": "biological product"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C.\n\t\t\t 262", "@value": "usc/42/262"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "header": {"#tail": "\n        ", "#text": "Biological\n\t\t\t product"}, "#text": "\n        ", "@id": "ID16b584086b464a0bad32207854cdac97"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " has the meaning given such term in ", "#text": "drug"}, "#text": "The\n\t\t\t term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 201 of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 321", "@value": "usc/21/321"}, "@parsable-cite": "usc/21/321", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "header": {"#tail": "\n        ", "#text": "Drug"}, "#text": "\n        ", "@id": "IDbaf18e10eab34690843645043ba44ecc"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " means a product\n\t\t\t that is a qualifying treatment for HIV/AIDS and that has a significant use for\n\t\t\t other diseases.", "#text": "dual use product"}, "#text": "The term "}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "header": {"#tail": "\n        ", "#text": "Dual use\n\t\t\t product"}, "#text": "\n        ", "@id": "ID3a7672ad63684096a1e1faea5eb695f3"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " means the Prize Fund for HIV/AIDS established under\n\t\t\t section 7.", "#text": "Fund"}, "#text": "The\n\t\t\t term "}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "header": {"#tail": "\n        ", "#text": "Fund"}, "#text": "\n        ", "@id": "ID03646dfbda3f4155906833affea79e72"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " means the\n\t\t\t approval of an application under ", "#text": "market clearance"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or the approval of a biologics license application\n\t\t\t under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n              ", "@legal-doc": "usc"}}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "subsection (a) of section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C.\n\t\t\t 262", "@value": "usc/42/262"}], "@entity-type": "law-citation", "#text": "\n            "}]}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "header": {"#tail": "\n        ", "#text": "Market\n\t\t\t clearance"}, "#text": "\n        ", "@id": "IDf18b6173e6154d8e835c2c81d4fcd7f1"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", for purposes\n\t\t\t of the Prize Fund for HIV/AIDS.", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "term": {"#tail": " means an antiretrovial drug, biological product, vaccine, or\n\t\t\t other treatment primarily used for HIV/AIDS that has been certified as a\n\t\t\t qualifying product by the ", "#text": "qualifying treatment for\n\t\t\t HIV/AIDS"}, "#text": "The term "}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "header": {"#tail": "\n        ", "#text": "Qualifying\n\t\t\t treatment for HIV/AIDS"}, "#text": "\n        ", "@id": "ID793dea4958834881b3ddf78079abab5a"}], "#text": "\n      ", "@id": "IDd1fca5d07f1342b6b7b01591ec08e19b"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n\t\t\t", "#text": "Elimination of\n\t\t\t exclusive rights to market drugs and biological products"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", relevant\n\t\t\t provisions of the ", "@entity-type": "uscode", "#text": "title 35, United States Code", "@value": "usc/35"}, "#text": "Notwithstanding ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": "\n\t\t\t (including amendments made by the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}, "@parsable-cite": "usc/21/301", "#text": "\n              ", "@legal-doc": "usc"}}, {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Drug Price Competition and Patent Term\n\t\t\t Restoration Act of 1984", "@value": "Drug Price Competition and Patent Term Restoration Act of 1984"}, "term": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "Hatch-Waxman Act", "@value": "Hatch-Waxman Act"}, "#text": "\n              "}, "#tail": "), the ", "@entity-type": "law-citation", "external-xref": {"#tail": "; commonly referred to as the\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 98\u2013417", "@value": "public-law/98/417"}, "@parsable-cite": "pl/98/417", "#text": "\n              ", "@legal-doc": "public-law"}, "#text": "\n            "}, {"#tail": ", and any other provision of\n\t\t\t law providing any patent right or exclusive marketing period for any qualifying\n\t\t\t treatment for HIV/AIDS or manufacturing process for a qualifying treatment for\n\t\t\t HIV/AIDS (such as pediatric extensions under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Medicare Prescription Drug, Improvement,\n\t\t\t and Modernization Act of 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 108\u2013173", "@value": "public-law/108/173"}, "@parsable-cite": "pl/108/173", "#text": "\n              ", "@legal-doc": "public-law"}}, {"#tail": " or orphan drug marketing exclusivity\n\t\t\t under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505A of the Federal Food,\n\t\t\t Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355a", "@value": "usc/21/355a"}, "@parsable-cite": "usc/21/355a", "#text": "\n              ", "@legal-doc": "usc"}}, {"#tail": "), no\n\t\t\t person shall have the right to exclusively manufacture, distribute, sell, or\n\t\t\t use a qualifying treatment for HIV/AIDS or a manufacturing process for a\n\t\t\t qualifying treatment for HIV/AIDS in interstate commerce, including the\n\t\t\t exclusive right to rely on health registration data or the 30-month\n\t\t\t stay-of-effectiveness period for Orange Book patents under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subchapter B of chapter V of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:V/sch:B"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 360aa et seq.", "@value": "usc/21/360aa/etseq"}, "@parsable-cite": "usc/21/360aa", "#text": "\n              ", "@legal-doc": "usc"}}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(j) of\n\t\t\t such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(j)", "@value": "usc/21/355/j"}, "@parsable-cite": "usc/21/355", "#text": "\n              ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "ID33f59201f64a455fac031efa32bde0db"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "A\n\t\t\t person that is eligible for prize payments from the Prize Fund for HIV/AIDS\n\t\t\t shall receive such payments\u2014"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Remuneration"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:5/ss:a", "@proposed": "true"}, "#text": "in lieu of any\n\t\t\t remuneration the person would have otherwise received for the exclusive\n\t\t\t marketing, distribution, sale, or use of a qualifying treatment for HIV/AIDS or\n\t\t\t manufacturing process for a qualifying treatment for HIV/AIDS but for the\n\t\t\t application of "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID673f377f59fa40ba97bdebc7fe8e3013", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "in addition to\n\t\t\t any other remuneration that such person receives by reason of the nonexclusive\n\t\t\t marketing, distribution, sale, or use of the qualifying treatment for HIV/AIDS\n\t\t\t or manufacturing process for a qualifying treatment for HIV/AIDS."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID67d470362fe7444cbad8f64db30b4ecd", "#text": "\n          "}], "#text": "\n        ", "@id": "IDe413d387a4a24312a3f2b21f3c3b5a9d"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "This\n\t\t\t section shall apply only with respect to the marketing, distribution, sale, or\n\t\t\t use of a qualifying treatment for HIV/AIDS or a manufacturing process for a\n\t\t\t qualifying treatment for HIV/AIDS that occurs on or after October 1,\n\t\t\t 2014."}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Application"}, "#text": "\n        ", "@id": "ID18e19ed29a394466aeaff6d5fdb23fa3"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall apply only with respect to the\n\t\t\t manufacture, distribution, marketing, sale, or use of the product for the\n\t\t\t treatment of HIV/AIDS.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:5/ss:a", "@proposed": "true"}, "#text": "In the case of a dual use product, the elimination of\n\t\t\t exclusive rights under "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Dual use\n\t\t\t products"}, "#text": "\n        ", "@id": "id48DC004A1DEA4BAFA72162BEF886FC21"}], "#text": "\n      ", "@id": "ID81bc1e018d1d49c5950607388c35fd50"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be limited to qualifying\n\t\t\t treatments for HIV/AIDS, as defined in ", "@entity-type": "act", "#text": "section 8", "@value": "Prize Fund for HIV|AIDS Act/s:8", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "section 4", "@value": "Prize Fund for HIV|AIDS Act/s:4", "@proposed": "true"}], "#text": "Prize\n\t\t\t payments from the Fund under ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n      ", "#text": "Qualifying\n\t\t\t treatments for HIV/AIDS"}, "#text": "\n      ", "@id": "ID71b3e6331d774770adaa600ec03a3311"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "7."}, "header": {"#tail": "\n\t\t\t", "#text": "Prize fund for\n\t\t\t HIV/AIDS"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (d)", "@value": "Prize Fund for HIV|AIDS Act/s:7/ss:d", "@proposed": "true"}, "term": {"#tail": ", which shall consist of\n\t\t\t amounts appropriated to the Fund and amounts credited to the Fund under\n\t\t\t ", "#text": "Prize Fund for HIV/AIDS"}, "#text": "There\n\t\t\t is hereby established in the Treasury of the United States a revolving fund to\n\t\t\t be known as the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Establishment"}, "#text": "\n        ", "@id": "ID48a89a915d0e431295b166622dc2376f"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall\n\t\t\t designate a ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " and other officials as needed to administer the\n\t\t\t Fund.", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Prize fund\n\t\t\t administration"}, "#text": "\n        ", "@id": "ID984d6041926e42b2accf6b64d0e265cd"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall appoint an\n\t\t\t advisory board for the Fund.", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Advisory\n\t\t\t board"}, "#text": "\n        ", "@id": "ID4f2ac970e3d847229eb134d28e61e872"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall credit\n\t\t\t to the Fund the interest on, and the proceeds from sale or redemption of,\n\t\t\t obligations held in the Fund.", "@entity-type": "federal-body", "#text": "Secretary of the Treasury", "@entity-id": "2000"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Amounts\n\t\t\t credited to the Fund"}, "#text": "\n        ", "@id": "idE936F2E332E8424B83C792679D151276"}], "#text": "\n      ", "@id": "ID26d5689df6b74185aad4e3e336290eb5"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "8."}, "header": {"#tail": "\n\t\t\t", "#text": "Prize payments\n\t\t\t for medical innovation"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t shall award to persons described in ", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, {"#tail": " prize payments for medical\n\t\t\t innovation relating to a qualifying treatment for HIV/AIDS, or a new\n\t\t\t manufacturing process for such a qualifying treatment for HIV/AIDS.", "@entity-type": "act", "#text": "subsection (b)", "@value": "Prize Fund for HIV|AIDS Act/s:8/ss:b", "@proposed": "true"}], "#text": "For\n\t\t\t fiscal year 2015, and each subsequent fiscal year, the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Award"}, "#text": "\n        ", "@id": "IDf7750cda0ae54810a5a67315d839c1ec"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " a person shall\n\t\t\t be\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:8/ss:a", "@proposed": "true"}, "#text": "To\n\t\t\t be eligible to receive a prize payment under "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Eligibility"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of a\n\t\t\t qualifying treatment for HIV/AIDS that is a drug or biological product, the\n\t\t\t first person to receive market clearance with respect to the drug or biological\n\t\t\t product;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "IDc4f5a260b81b4c6eaaff67864b098441", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of a\n\t\t\t manufacturing process for a qualifying treatment for HIV/AIDS, the holder of\n\t\t\t the patent with respect to such process; or"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID2a33d18f63954bd88bf97beee5760232", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of\n\t\t\t open source contributions with respect to a qualifying treatment for HIV/AIDS,\n\t\t\t the persons or communities that openly shared knowledge, data, materials, and\n\t\t\t technology on a royalty-free and nondiscriminatory basis."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID9d713fc960fe49cf87cb5b26b73a5a3a", "#text": "\n          "}], "#text": "\n        ", "@id": "IDaa7f039a7d5640aea58730eb1097eae6"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall, by regulation, establish criteria for the selection\n\t\t\t of recipients, and for determining the amount, of prize payments under this\n\t\t\t section. Such criteria shall include consideration of the following:", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Criteria"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "The number of\n\t\t\t patients who benefit from the qualifying treatment for HIV/AIDS or\n\t\t\t manufacturing process involved."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID8103e70eb9694e51ad63ab24733445c1", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall provide for cases where drugs,\n\t\t\t biological products, or manufacturing processes are developed at roughly the\n\t\t\t same time, so that the comparison is to products that were not recently\n\t\t\t developed.", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "The incremental\n\t\t\t therapeutic benefit of the qualifying treatment for HIV/AIDS or manufacturing\n\t\t\t process involved as compared to existing drugs, biological products, and\n\t\t\t manufacturing processes available to treat the same disease or condition,\n\t\t\t except that the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID7426037eeac5448bb5a1171e49feb09e", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Improved\n\t\t\t efficiency of manufacturing processes for drugs or biological processes."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID4079166196894549b5b6aa26317e5a17", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The extent to\n\t\t\t which knowledge, data, materials, and technology that are openly shared have\n\t\t\t contributed to the successful development of new products or improved processes\n\t\t\t for manufacturing products."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "ID0d3ae78a95d9438dad7ba548fdfef758", "#text": "\n          "}], "#text": "\n        ", "@id": "IDb2b4c8acd3354c809230f49306297c4d"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t comply with the following:", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "In\n\t\t\t awarding prize payments under this section, the "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Requirements"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall continue to make prize payments for the existing qualifying\n\t\t\t treatment or manufacturing process to the degree that the new qualifying\n\t\t\t treatment or manufacturing process was based on or benefitted from the\n\t\t\t development of the existing qualifying treatment or manufacturing\n\t\t\t process.", "@entity-type": "federal-body", "#text": "Prize\n\t\t\t Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "In cases where a\n\t\t\t new qualifying treatment for HIV/AIDS or manufacturing process for a qualifying\n\t\t\t treatment of HIV/AIDS offers an improvement over an existing qualifying\n\t\t\t treatment for HIV/AIDS or manufacturing process for a qualifying treatment and\n\t\t\t such new qualifying treatment or manufacturing process competes with or\n\t\t\t replaces the existing qualifying treatment or manufacturing process, the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "IDb80b0eb6715c4409a252982443b4d0fd", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may award prize payments for a qualifying treatment for HIV/AIDS or a\n\t\t\t manufacturing process for a qualifying treatment for HIV/AIDS for not more than\n\t\t\t 10 fiscal years, regardless of the term of any related patents.", "@entity-type": "federal-body", "#text": "Prize Fund\n\t\t\t Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "The "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDc9c34dc559064676981667c54296249b", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may not award a prize payment for any single\n\t\t\t qualifying treatment for HIV/AIDS or manufacturing process for a qualifying\n\t\t\t treatment in an amount that exceeds 50 percent of the total amount appropriated\n\t\t\t to the Fund for that year.", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "For any fiscal\n\t\t\t year, the "}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID303ab509a5a84409a6a1a82fa29cd9c5", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall determine whether and in what amount to award a prize\n\t\t\t payment for the qualifying treatment for HIV/AIDS not later than the end of the\n\t\t\t fourth full calendar-year quarter following the calendar-year quarter in which\n\t\t\t the qualifying treatment for HIV/AIDS receives market clearance.", "@entity-type": "federal-body", "#text": "Prize\n\t\t\t Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "For every\n\t\t\t qualifying treatment for HIV/AIDS that receives market clearance, the "}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "IDa532e4b64928458791e63c708709282b", "#text": "\n          "}], "#text": "\n        ", "@id": "IDf178175b18ec46e2b5e1c07f83048408"}], "#text": "\n      ", "@id": "ID2f298986d61f4f82b9e8c06ab3f799f5"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "9."}, "header": {"#tail": "\n\t\t\t", "#text": "Open source\n\t\t\t dividend prizes"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "In order to induce greater access and the open sharing of\n\t\t\t knowledge, data, materials, and technology, at least 5 percent of the prize\n\t\t\t payments from the Fund shall be dedicated to Open Source Dividend\n\t\t\t Prizes."}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "IDce77e284b8ed4e83a0e5ea9d0ecac831"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Procedures"}, "paragraph": [{"#tail": "\n        ", "@id": "id3A9356F98D1F4DAC8BE420D3BAC9E7CB", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall adopt procedures for the\n\t\t\t allocation of Open Source Dividend Prizes. Such procedures shall\u2014", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "The "}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "be fully\n\t\t\t transparent regarding the process for evaluating the value of open sharing of\n\t\t\t knowledge, data, materials, and technology;"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "ID27beefcd7ad440c7b90946437db642b6", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "section 7", "@value": "Prize Fund for HIV|AIDS Act/s:7", "@proposed": "true"}, "#text": "reward the open,\n\t\t\t nondiscriminatory, and royalty-free sharing of knowledge, data, materials, and\n\t\t\t technology that has contributed to the development of the new qualifying\n\t\t\t treatment for HIV/AIDS or manufacturing processes that are rewarded under\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "ID32ec8eda11e24c51ae150c1f9b3ebadc", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", provide for a\n\t\t\t time-limited period of nominations for persons or communities whose\n\t\t\t contributions were considered useful, including the evidence to support such\n\t\t\t nominations to describe the significance of the contribution; and", "@entity-type": "act", "#text": "section 7", "@value": "Prize Fund for HIV|AIDS Act/s:7", "@proposed": "true"}, "#text": "in the case of\n\t\t\t rewards for contributing to the development of new qualifying treatment for\n\t\t\t HIV/AIDS or manufacturing processes rewarded under "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "ID29566d735be04db5bc4c69ed534c7a6d", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "provide for rules\n\t\t\t and procedures to protect against conflicts of interest."}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "@id": "IDfa668cd7b46d42aa839bc7d58683d021", "#text": "\n            "}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", and the evidence supporting such nominations, shall be\n\t\t\t public. The public shall be allowed to provide commentary and additional\n\t\t\t evidence on such nominations before awards are made.", "@entity-type": "act", "#text": "paragraph (1)(C)", "@value": "Prize Fund for HIV|AIDS Act/s:9/ss:b/p:1/sp:C", "@proposed": "true"}, "#text": "The nominations described in\n\t\t\t "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Public\n\t\t\t availability of nominations"}, "#text": "\n          ", "@id": "idADA372C1F6214C3D80810A44071B2093"}], "#text": "\n        ", "@id": "ID84f7e112f1844dbba6fc27048103c28e"}], "#text": "\n      ", "@id": "IDcf1d5afde68345729cdc6b33976a10a2"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "10."}, "header": {"#tail": "\n\t\t\t", "#text": "Competitive\n\t\t\t intermediaries for funding interim technologies"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may authorize multiple nonprofit\n\t\t\t intermediaries to manage Fund payments to reward projects for interim research\n\t\t\t and development of new qualifying treatments for HIV/AIDS, or for open source\n\t\t\t dividend prizes. Such intermediaries shall compete for funding from non-Federal\n\t\t\t entities that co-fund the Fund.", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "ID138d5314349c4eefa6781aa5b8cfc113"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Prizes\n\t\t\t awarded by competitive intermediaries shall be available to persons or\n\t\t\t communities that provide open, nondiscriminatory, and royalty-free licenses to\n\t\t\t relevant intellectual property rights."}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Availability"}, "#text": "\n        ", "@id": "IDf035fc1e46114d6b856c81ada120febb"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall adopt rules to ensure the transparency and\n\t\t\t accountability of any entities authorized to act as competitive intermediaries\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:10/ss:a", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Rules"}, "#text": "\n        ", "@id": "ID29261ae7d33c4cb4b3fe33fe01aaa768"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall determine how much of the Fund\n\t\t\t shall be managed by competitive intermediaries to reward projects for interim\n\t\t\t research and development of new qualifying treatments for HIV/AIDS or for open\n\t\t\t source dividend prizes.", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Allocation"}, "#text": "\n        ", "@id": "IDdf8b065b16c740e587a01c55340d972e"}], "#text": "\n      ", "@id": "IDf64feece547f4f8ebd8277c82a775a52"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "11."}, "header": {"#tail": "\n\t\t\t", "#text": "Special\n\t\t\t transition rules"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 8(d)(3)", "@value": "Prize Fund for HIV|AIDS Act/s:8/ss:d/p:3", "@proposed": "true"}, "#text": "A qualifying treatment for HIV/AIDS that is on the market\n\t\t\t on October 1, 2014, shall remain eligible for prize payments for not more than\n\t\t\t 10 fiscal years, consistent with "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "ID5e63259ebc414465afd43ac9bbd2039e"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:11/ss:a", "@proposed": "true"}, {"#tail": " shall calculate the incremental value of the qualifying treatment for\n\t\t\t HIV/AIDS as of the date on which the qualifying treatment for HIV/AIDS was\n\t\t\t first introduced in the market.", "@entity-type": "federal-body", "#text": "Prize Fund\n\t\t\t Director", "@value": "Prize Fund Director", "@proposed": "true"}], "#text": "In determining the amount of a prize payment for a\n\t\t\t qualifying treatment for HIV/AIDS described in "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Determination\n\t\t\t of value"}, "#text": "\n        ", "@id": "IDca4f434ef7d84a78840de82b748f29e0"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prize Fund for HIV|AIDS Act/s:11/ss:a", "@proposed": "true"}, {"#tail": " may award\u2014", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}], "#text": "With respect to qualifying treatment for HIV/AIDS\n\t\t\t described in "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Maximum\n\t\t\t amount"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "of the amount\n\t\t\t appropriated to the Fund for fiscal year 2015, not more than 90 percent of such\n\t\t\t amount; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID1c96668285944e99b520f3f18f3f392d", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "of the amount\n\t\t\t appropriated to the Fund for each of the succeeding 9 fiscal years, not more\n\t\t\t than a percentage of such amount that is equal to 9 percent less the percentage\n\t\t\t applicable to the preceding fiscal year under this subsection."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID0ce63a5cc3f6420ea3a29a90d304c246", "#text": "\n          "}], "#text": "\n        ", "@id": "ID9b904bc335d84188bab2bd7a47fc4f8a"}], "#text": "\n      ", "@id": "ID2fc8dc3581474423b82600a7fcd04f39"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall establish an\n\t\t\t arbitration procedure to determine an equitable division of any prize payments\n\t\t\t under this Act among the patent owners and the person who first received market\n\t\t\t clearance for the qualifying treatment for HIV/AIDS.", "@entity-type": "federal-body", "#text": "Prize Fund Director", "@value": "Prize Fund Director", "@proposed": "true"}, "#text": "In the case of a qualifying treatment for\n\t\t\t HIV/AIDS that is on the market on October 1, 2014, and subject to patents owned\n\t\t\t by a party other than the person who first received market clearance for the\n\t\t\t qualifying treatment for HIV/AIDS, the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "12."}, "header": {"#tail": "\n      ", "#text": "Arbitration"}, "#text": "\n      ", "@id": "ID8ed176287888492984c52826387a8251"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "13."}, "header": {"#tail": "\n\t\t\t", "#text": "Funding"}, "subsection": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Appropriations"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n          ", "@entity-type": "auth-auth-approp", "#text": "For ", "{http://namespaces.cato.org/catoxml}funds-and-year": [{"#tail": " there are authorized to be\n\t\t\t appropriated to the Fund, ", "#text": "fiscal year 2015,"}, {"#tail": " ", "#text": "such sums as may be necessary", "@amount": "indefinite", "@year": "2015"}], "{http://namespaces.cato.org/catoxml}property": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "this\n\t\t\t Act", "@value": "Prize Fund for HIV|AIDS Act", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Start-up\n\t\t\t costs"}, "#text": "\n          ", "@id": "IDcc6769b27ea5451ca3069bb6d91cc46a"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ").", "@entity-type": "federal-body", "#text": "Secretary of\n\t\t\t Commerce", "@entity-id": "1300"}, "@entity-type": "auth-auth-approp", "#text": "For fiscal year 2015 and each subsequent fiscal\n\t\t\t year, there is authorized to be appropriated to the Fund, and there is\n\t\t\t appropriated, out of any funds in the Treasury not otherwise appropriated, an\n\t\t\t amount equal to 0.02 percent of the gross domestic product of the United States\n\t\t\t for the preceding fiscal year (as such amount is determined by the "}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Program\n\t\t\t implementation"}, "#text": "\n          ", "@id": "ID5cc76b8f1e804c9e89fbb7f32d88ca7e"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Funds\n\t\t\t appropriated to the Fund for a fiscal year shall remain available for\n\t\t\t expenditure in accordance with this Act until the end of the 3-year period\n\t\t\t beginning on October 1 of such fiscal year. Any such funds that are unexpended\n\t\t\t at the end of such period shall revert to the Treasury."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n          ", "#text": "Availability"}, "#text": "\n          ", "@id": "id5EC4FCB8DE464B9AAFFBBF178FA78C8C"}], "#text": "\n        ", "@id": "ID9502d1945b8a4bce877b60722511f91c"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Imposition of\n\t\t\t annual fee on health insurance providers"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", not later than the annual payment\n\t\t\t date of each calendar year beginning after 2014, a fee in an amount determined\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (3)", "@value": "Prize Fund for HIV|AIDS Act/s:13/ss:b/p:3", "@proposed": "true"}], "#text": "Each covered entity engaged in the business of providing\n\t\t\t health insurance shall pay to the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "ID87c97f9d5328498cb87df23d39d351af", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", which in no event, may be later than September 30 of such calendar\n\t\t\t year.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": " means, with respect to any calendar year, a date determined by the\n\t\t\t ", "#text": "annual payment\n\t\t\t date"}, "#text": "For purposes of this section, the term "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Annual payment\n\t\t\t date"}, "#text": "\n          ", "@id": "IDc1204cdf160446e4a95f12b6cdab4852", "@commented": "no"}, {"#tail": "\n      ", "@id": "IDb1be87456c7d41999ddc07b319c7f0de", "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Determination\n\t\t\t of fee amount"}, "@display-inline": "no-display-inline", "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " multiplied by\n\t\t\t the ratio of the number of persons receiving treatments for HIV/AIDS that are\n\t\t\t insured in the private sector to the number of persons receiving treatments for\n\t\t\t HIV/AIDS who received insurance or reimbursements or care from the public\n\t\t\t sector.", "@entity-type": "act", "#text": "subsection (a)(2)", "@value": "Prize Fund for HIV|AIDS Act/s:13/ss:a/p:2", "@proposed": "true"}, "#text": "The total of all fees paid by all covered entities for\n\t\t\t any given year shall be the amount described in "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "In\n\t\t\t general"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id3757C1CA3B6746BCA2133588ED59C0E1", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " during the preceding\n\t\t\t calendar year, to the sum of such net premiums for all covered entities,\n\t\t\t multiplied by the amount under ", "@entity-type": "act", "#text": "subsection (c)", "@value": "Prize Fund for HIV|AIDS Act/s:13/ss:c", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Prize Fund for HIV|AIDS Act/s:13/ss:b/p:3/sp:A", "@proposed": "true"}], "#text": "With respect to each covered entity, the fee under\n\t\t\t this section for any calendar year shall be equal to the ratio of the covered\n\t\t\t entity's net premiums written with respect to health insurance for any United\n\t\t\t States health risk taken into account under "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "Individual\n\t\t\t contributions"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id3F77B38F23FB418EB6DED2FB0C17A4D3", "@commented": "no"}], "@commented": "no"}], "#text": "\n        ", "@id": "ID0b307ddb880e4cf9911d118f20b700f7"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the net premiums\n\t\t\t written with respect to health insurance for any United States health risk that\n\t\t\t are taken into account during any calendar year with respect to any covered\n\t\t\t entity shall be determined as follows:", "@entity-type": "act", "#text": "subsection (b)(3)", "@value": "Prize Fund for HIV|AIDS Act/s:13/ss:b/p:3", "@proposed": "true"}, "#text": "For purposes of "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Amounts taken\n\t\t\t into account"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are not\n\t\t\t more than $25,000,000, the percentage of net premiums written that are taken\n\t\t\t into account is 0 percent."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "idE11E8A5787AC4FD4A214B83380C0F0F2", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are more\n\t\t\t than $25,000,000 but less than $50,000,000, the percentage of net premiums\n\t\t\t written that are taken into account is 50 percent."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idB938B34EF79D401B8D3FE259B4D724C3", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are\n\t\t\t $50,000,000 or more, the percentage of net premiums written that are taken into\n\t\t\t account is 100 percent."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "id4D0162576CEB4DF1B1F9A5FDD1962879", "#text": "\n          "}], "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idD90F24410DF04B0DB3FCC483419B0E69", "@commented": "no"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Covered\n\t\t\t entity"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "term": {"#tail": " means any entity which provides health insurance for any United\n\t\t\t States health risk.", "#text": "covered\n\t\t\t entity"}, "#text": "For purposes of this section, the term "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "id6B4E499CE57B445BBD006CEFA5E960EB"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Such\n\t\t\t term does not include any governmental entity."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Exclusion"}, "#text": "\n          ", "@id": "ID2e06316d8f494c8eb2f20252d9d10e7d"}], "#text": "\n        ", "@id": "id27052F4D01884EA6A98CE0A3BE5F5B95"}], "#text": "\n      ", "@id": "ID763cbcb959d6443f9f14a226ef635e39"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "14."}, "header": {"#tail": "\n\t\t\t", "#text": "Donor\n\t\t\t Innovation Prize Fund"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": ".", "#text": "Donor Innovation Prize\n\t\t\t Fund"}, "#text": "In order to further separate product prices from research\n\t\t\t and development incentives and to facilitate the supply of low-cost generic\n\t\t\t drugs for the treatment of HIV/AIDS in developing countries, there is\n\t\t\t established in the Treasury of the United States a "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "IDee9bcae86e9a4a78a0ec12ee85f5075b"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The amount in the Donor Innovation Prize Fund shall consist\n\t\t\t of\u2014"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Amount in\n\t\t\t Fund"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " that is equal to 10 percent\n\t\t\t of the amount of money estimated by such ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " as the cost of qualifying\n\t\t\t treatments for HIV/AIDS used by programs supported by the President\u2019s Emergency\n\t\t\t Plan for AIDS Relief (commonly referred to as ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "term": {"#tail": ") or other\n\t\t\t federally supported programs to fund the treatment of HIV/AIDS in developing\n\t\t\t countries; and", "#text": "PEPFAR"}, "#text": "an amount set\n\t\t\t aside by the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "id97330E147A0C4CA2850D22384E12A1A6", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (d)", "@value": "Prize Fund for HIV|AIDS Act/s:14/ss:d", "@proposed": "true"}, "#text": "other amounts\n\t\t\t donated to the Fund as described in "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "id0473FADC84EE48DD9B7F089CD8B9F721", "#text": "\n          "}], "#text": "\n        ", "@id": "ID5fe939d781b540abb49f79721dc85224"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (referred to in\n\t\t\t this section as the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "term": {"#tail": ") shall use the funds from the Donor\n\t\t\t Innovation Prize Fund to reward the owners and developers of products that\n\t\t\t permit open competition for products in developing countries, either by not\n\t\t\t patenting products, providing nondiscriminatory royalty-free open licenses to\n\t\t\t all patents and other intellectual property claims on at least a field of use\n\t\t\t for the treatment of HIV/AIDS in developing countries, or through licenses to\n\t\t\t the Medicine Patent Pool.", "#text": "Secretary"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Use of\n\t\t\t funds"}, "#text": "\n        ", "@id": "ID8fdf274495ae4076a6143e530d8c5e77"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall encourage other donors and\n\t\t\t developing country governments to contribute a similar fraction of drug\n\t\t\t purchase budgets to the Donor Innovation Prize Fund, in order to facilitate\n\t\t\t greater competition for generic drugs, while providing a sustainable source of\n\t\t\t rewards for innovation.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Encouragement\n\t\t\t by Secretary"}, "#text": "\n        ", "@id": "ID111604746aa54d15875e9001383df1ff"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish and award prize payments from the Donor Innovation\n\t\t\t Prize Fund by applying similar eligibility rules, selection criteria, and\n\t\t\t requirements as are applied with respect to prize payments awarded from the\n\t\t\t Prize Fund for HIV/AIDS under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "section 8", "@value": "Prize Fund for HIV|AIDS Act/s:8", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(e)"}, "header": {"#tail": "\n        ", "#text": "Prizes"}, "#text": "\n        ", "@id": "ID19b6dea0ed2e4c22a663bc178a2e19d3"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall adopt procedures to ensure that the operation of the Donor\n\t\t\t Innovation Prize Fund is transparent and supported by a description of the\n\t\t\t methods, data sources, assumptions, outcomes, and related information that will\n\t\t\t allow the public to understand how the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " reaches its criteria-setting\n\t\t\t and award decisions.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(f)"}, "header": {"#tail": "\n        ", "#text": "Transparency"}, "#text": "\n        ", "@id": "ID3cbaae2e8db9445aba8016495a637f38"}], "#text": "\n      ", "@id": "IDb766e7bf62cd4db0a0213a6526807ef2"}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-03-20"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S626 IS: Prize Fund for HIV/AIDS Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}